Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants.
Stubbins RJ et al.
Leukemia, 2025
40335619 (PubMed )
Supplement: 41375_2025_2635_MOESM5_ESM.xls › CHEK2_Supplemental_Table_4_v25
Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis.
Wen S et al.
Nature Genetics, 2025
39948438 (PubMed )
Supplement: 41588_2025_2085_MOESM4_ESM.xlsx › ST22
Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme.
Sosinsky A et al.
Nature Medicine, 2024
38200255 (PubMed )
Supplement: 41591_2023_2682_MOESM3_ESM.xlsx › Table_S1
Clarifying the biological significance of the CHK2 K373E somatic mutation discovered in The Cancer Genome Atlas database.
Higashiguchi M et al.
Febs Letters, 2016
Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation.
Sodha N et al.
Cancer Research, 2006
Regulation of Chk2 phosphorylation by interaction with protein phosphatase 2A via its B' regulatory subunit.
Dozier C et al.
Biology of the Cell, 2004
Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain.
Ahn JY et al.
The Journal of Biological Chemistry, 2002
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
Lee SB et al.
Cancer Research, 2001
Select a paper to view details